{
  "input": {
    "mode": "revise",
    "query": {
      "entity": "Generalised pustular psoriasis",
      "relation": "indication"
    },
    "tegraph_snapshot": {
      "nodes": [
        {
          "id": "drug_acitretin",
          "type": "Drug",
          "label": "Acitretin",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_adalimumab",
          "type": "Drug",
          "label": "Adalimumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_etanercept",
          "type": "Drug",
          "label": "Etanercept",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_infliximab",
          "type": "Drug",
          "label": "Infliximab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_secukinumab",
          "type": "Drug",
          "label": "Secukinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ixekizumab",
          "type": "Drug",
          "label": "Ixekizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_austedo",
          "type": "Drug",
          "label": "Austedo",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_methotrexate",
          "type": "Drug",
          "label": "Methotrexate",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_cyclosporine",
          "type": "Drug",
          "label": "Cyclosporine",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_tildrakizumab",
          "type": "Drug",
          "label": "Tildrakizumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_brodalumab",
          "type": "Drug",
          "label": "Brodalumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "drug_ustekinumab",
          "type": "Drug",
          "label": "Ustekinumab",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "disease_generalised_pustular_psoriasis",
          "type": "Disease",
          "label": "Generalised pustular psoriasis",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_IL17A",
          "type": "Target",
          "label": "IL-17A",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "target_TNF_alpha",
          "type": "Target",
          "label": "TNF-alpha",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "pathway_inflammatory_response",
          "type": "Pathway",
          "label": "Inflammatory Response Pathway",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "phenotype_skin_inflammation",
          "type": "Phenotype",
          "label": "Skin Inflammation Phenotype",
          "attrs": {
            "agent": "Proponent"
          }
        },
        {
          "id": "n_ot_acitretin",
          "type": "Target",
          "label": "OffTarget of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_acitretin",
          "type": "Pathway",
          "label": "Risk Pathway for Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_acitretin",
          "type": "Phenotype",
          "label": "Adverse Effects of Acitretin",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_adalimumab",
          "type": "Target",
          "label": "OffTarget of Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_adalimumab",
          "type": "Pathway",
          "label": "Risk Pathway for Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_adalimumab",
          "type": "Phenotype",
          "label": "Adverse Effects of Adalimumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_infliximab",
          "type": "Target",
          "label": "OffTarget of Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_infliximab",
          "type": "Pathway",
          "label": "Risk Pathway for Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_infliximab",
          "type": "Phenotype",
          "label": "Adverse Effects of Infliximab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_ot_secukinumab",
          "type": "Target",
          "label": "OffTarget of Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_rp_secukinumab",
          "type": "Pathway",
          "label": "Risk Pathway for Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        },
        {
          "id": "n_adv_secukinumab",
          "type": "Phenotype",
          "label": "Adverse Effects of Secukinumab",
          "attrs": {
            "agent": "Skeptic"
          }
        }
      ],
      "edges": [
        {
          "source": "drug_acitretin",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Acitretin通过IL-17A调节免疫反应"
        },
        {
          "source": "drug_adalimumab",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Adalimumab抑制TNF-alpha，减少炎症"
        },
        {
          "source": "drug_etanercept",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Etanercept靶向TNF-alpha，缓解炎症"
        },
        {
          "source": "drug_infliximab",
          "target": "target_TNF_alpha",
          "relation": "acts_on",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "Infliximab通过抑制TNF-alpha发挥作用"
        },
        {
          "source": "drug_secukinumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Secukinumab特异性抑制IL-17A"
        },
        {
          "source": "drug_ixekizumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "Ixekizumab靶向IL-17A以改善症状"
        },
        {
          "source": "drug_methotrexate",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Methotrexate在炎症通路中有作用"
        },
        {
          "source": "drug_cyclosporine",
          "target": "pathway_inflammatory_response",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Cyclosporine通过抑制免疫系统缓解炎症"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Tildrakizumab靶向IL-17A有效"
        },
        {
          "source": "drug_brodalumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Brodalumab靶向IL-17A以改善临床症状"
        },
        {
          "source": "drug_ustekinumab",
          "target": "target_IL17A",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Ustekinumab抑制IL-17及IL-23"
        },
        {
          "source": "target_IL17A",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "IL-17A在炎症反应通路中重要"
        },
        {
          "source": "target_TNF_alpha",
          "target": "pathway_inflammatory_response",
          "relation": "involved_in",
          "weight": 0.8,
          "agent": "Proponent",
          "rationale": "TNF-alpha在炎症反应通路中关键"
        },
        {
          "source": "pathway_inflammatory_response",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "causes",
          "weight": 0.85,
          "agent": "Proponent",
          "rationale": "炎症反应通路与病理状态关联"
        },
        {
          "source": "drug_acitretin",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Acitretin已用于治疗该状态"
        },
        {
          "source": "drug_adalimumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Adalimumab显示出疗效"
        },
        {
          "source": "drug_etanercept",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.75,
          "agent": "Proponent",
          "rationale": "Etanercept用作治疗选项"
        },
        {
          "source": "drug_infliximab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Infliximab用于该病的治疗"
        },
        {
          "source": "drug_secukinumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.7,
          "agent": "Proponent",
          "rationale": "Secukinumab治疗显示帮助"
        },
        {
          "source": "drug_ixekizumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.65,
          "agent": "Proponent",
          "rationale": "Ixekizumab在这一状态下得到了认可"
        },
        {
          "source": "drug_methotrexate",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Methotrexate用于治疗皮肤疾病"
        },
        {
          "source": "drug_cyclosporine",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.6,
          "agent": "Proponent",
          "rationale": "Cyclosporine有时用于此类疾病"
        },
        {
          "source": "drug_tildrakizumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.55,
          "agent": "Proponent",
          "rationale": "Tildrakizumab已显示效果"
        },
        {
          "source": "drug_brodalumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Brodalumab被探索用于此病症"
        },
        {
          "source": "drug_ustekinumab",
          "target": "disease_generalised_pustular_psoriasis",
          "relation": "supports",
          "weight": 0.5,
          "agent": "Proponent",
          "rationale": "Ustekinumab对相关症状有帮助"
        },
        {
          "source": "drug_acitretin",
          "target": "n_ot_acitretin",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_acitretin",
          "target": "n_rp_acitretin",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_acitretin",
          "target": "n_adv_acitretin",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_acitretin",
          "target": "H1",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        },
        {
          "source": "drug_adalimumab",
          "target": "n_ot_adalimumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_adalimumab",
          "target": "n_rp_adalimumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_adalimumab",
          "target": "n_adv_adalimumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_adalimumab",
          "target": "H2",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        },
        {
          "source": "drug_infliximab",
          "target": "n_ot_infliximab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_infliximab",
          "target": "n_rp_infliximab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_infliximab",
          "target": "n_adv_infliximab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_infliximab",
          "target": "H4",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        },
        {
          "source": "drug_secukinumab",
          "target": "n_ot_secukinumab",
          "relation": "acts_on",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "潜在的旁路影响"
        },
        {
          "source": "n_ot_secukinumab",
          "target": "n_rp_secukinumab",
          "relation": "involved_in",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "风险通路风险关联"
        },
        {
          "source": "n_rp_secukinumab",
          "target": "n_adv_secukinumab",
          "relation": "causes",
          "weight": 0.7,
          "agent": "Skeptic",
          "rationale": "可能导致不良表型"
        },
        {
          "source": "n_adv_secukinumab",
          "target": "H5",
          "relation": "refutes",
          "weight": 0.8,
          "agent": "Skeptic",
          "rationale": "风险成立将抵消益处"
        }
      ],
      "round_index": 4
    },
    "history": {
      "round": 4,
      "last_scores": [
        {
          "hypothesis_id": "H1",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Acitretin Risks",
                "pro": [
                  "n_adv_acitretin"
                ],
                "con": [
                  "H1"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Acitretin作用于IL-17A，并与病理状态关联"
            ],
            "safety_risk": [
              "存在较强的副作用风险，Skeptic指出可能导致不良表型"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Acitretin的长期安全性需进一步评估"
          ]
        },
        {
          "hypothesis_id": "H2",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Adalimumab Risks",
                "pro": [
                  "n_adv_adalimumab"
                ],
                "con": [
                  "H2"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Adalimumab靶向TNF-alpha，减少炎症"
            ],
            "safety_risk": [
              "副作用风险较高，存在可能导致不良表型的担忧"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Adalimumab的长期效果与安全性需进一步验证"
          ]
        },
        {
          "hypothesis_id": "H3",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.75,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Etanercept Risks",
                "pro": [
                  "n_adv_infliximab"
                ],
                "con": [
                  "H3"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Etanercept靶向TNF-alpha，缓解炎症"
            ],
            "safety_risk": [
              "存在较强副作用风险，可能影响应用价值"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Etanercept的真实疗效尚待更多数据支持"
          ]
        },
        {
          "hypothesis_id": "H4",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Infliximab Risks",
                "pro": [
                  "n_adv_infliximab"
                ],
                "con": [
                  "H4"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Infliximab抑制TNF-alpha发挥作用"
            ],
            "safety_risk": [
              "存在较强副作用，Skeptic表明可能导致不良反应"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Infliximab的使用安全性尚需验证"
          ]
        },
        {
          "hypothesis_id": "H5",
          "score": 0.48,
          "components": {
            "mechanism_fit": 0.7,
            "class_prior": 0.6,
            "pk_pd_feasibility": 0.5,
            "indication_plausibility": 0.5,
            "safety_risk": 0.3,
            "graph_bonus": 0.15,
            "conflict_penalty": 0.5
          },
          "graph_signals": {
            "support_weight": 0.7,
            "contradiction_weight": 0.8,
            "mechanistic_connectivity": false,
            "path_disjointness": 1,
            "conflict_hotspots": [
              {
                "topic": "Secukinumab Risks",
                "pro": [
                  "n_adv_secukinumab"
                ],
                "con": [
                  "H5"
                ]
              }
            ]
          },
          "rationales": {
            "mechanism_fit": [
              "Secukinumab特异性抑制IL-17A"
            ],
            "safety_risk": [
              "与潜在风险相结合，可能导致不良表型"
            ]
          },
          "confidence": "medium",
          "uncertainties": [
            "Secukinumab的疗效与安全性待进一步解析"
          ]
        },
        {
          "hypothesis_id": "H6",
          "score": 0.35,
          "confidence": "medium",
          "uncertainties": [
            "Ixekizumab的有效性与安全性仍待进一步调查"
          ]
        },
        {
          "hypothesis_id": "H7",
          "score": 0.1,
          "confidence": "low",
          "uncertainties": [
            "Austedo与此疾病的相关性未证明，疗效不确定"
          ]
        },
        {
          "hypothesis_id": "H8",
          "score": 0.25,
          "confidence": "low",
          "uncertainties": [
            "Methotrexate对皮肤病的疗效在此情况下不明确"
          ]
        },
        {
          "hypothesis_id": "H9",
          "score": 0.25,
          "confidence": "low",
          "uncertainties": [
            "Cyclosporine在此情境下的作用尚需证实"
          ]
        },
        {
          "hypothesis_id": "H10",
          "score": 0.35,
          "confidence": "medium",
          "uncertainties": [
            "Tildrakizumab的疗效与安全性仍需进一步探讨"
          ]
        },
        {
          "hypothesis_id": "H11",
          "score": 0.3,
          "confidence": "low",
          "uncertainties": [
            "Brodalumab的效果较少数据支持"
          ]
        },
        {
          "hypothesis_id": "H12",
          "score": 0.3,
          "confidence": "low",
          "uncertainties": [
            "Ustekinumab在此病症下的应用效果尚待证实"
          ]
        }
      ]
    },
    "thresholds": {
      "stop_delta": 0.03,
      "saturation_ratio": 0.65
    },
    "heuristic_priors": []
  },
  "output": {
    "revisions": [
      {
        "hypothesis_id": "H1",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "Acitretin Risks",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_acitretin",
            "via": [
              "target_IL17A"
            ],
            "to": "pathway_inflammatory_response",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "探讨Acitretin的长期安全性及其影响",
          "区分副作用的严重性与临床获益"
        ]
      },
      {
        "hypothesis_id": "H2",
        "graph_actions": [
          {
            "type": "stress_test_safety",
            "topic": "Adalimumab Risks",
            "expectation": "若风险成立，标注高权重 refutes 边",
            "assignee": "Skeptic"
          },
          {
            "type": "add_mechanism_link",
            "from": "drug_adalimumab",
            "via": [
              "target_TNF_alpha"
            ],
            "to": "pathway_inflammatory_response",
            "success_criteria": "形成至少2条不相交路径",
            "assignee": "Proponent"
          }
        ],
        "debate_focus": [
          "要求补充对Adalimumab潜在不良反应的论证",
          "确认其在治疗中可能的疗效与失败风险"
        ]
      }
    ],
    "pruned_hypotheses": [
      "H3",
      "H4",
      "H5"
    ],
    "seed_request": {
      "should_regenerate": true,
      "reason": "待评估的候选机制以讨论其有效性及风险，但当前缺少足够的机制连通性",
      "n": 4
    }
  }
}